Persistent Systems Ltd Q4 FY2025 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/d95jr0r4gxvxua8fc63q2dbx.pdf

Key Takeaways


Demand Environment

Sandeep Kalra: "we have not seen any cancellations, let me put it straight - we have not seen any cancellations, we are seeing a certain amount of feet dragging in terms of deal closures"

Vertical Performance

VerticalTrendCommentary
Healthcare & Life Sciences▲ Strong FY25, Q4 cautionGrew 33.6% YoY in Q4 and 54% for the full year, leading growth for six straight quarters. Government-funded research, clinical trial services and software equipment budgets have vanished overnight due to DOGE and USAID cuts, stressing the system. Management is reasonably confident the pipeline outside impacted accounts can sustain growth.
Banking & Financial Services▲ AcceleratingGrew 26.6% YoY in Q4 and 17.8% for the full year, with momentum picking up in the last two quarters. A large BFSI deal win last quarter drove vendor consolidation and higher sub-contracting costs.
Software & High-Tech▬ SubduedGrew only 9.7% YoY in Q4 and 3.7% for the full year, the weakest vertical. A large multi-year SaaS provider deal for enterprise-wide SASVA adoption was a bright spot.
Europe▲ OutperformingLed geographic growth at 30.6% YoY in Q4; a scaled European acquisition is a stated M&A priority for revenue diversification.
North America▲ SolidGrew 21.3% YoY in Q4 and 20.6% for the full year, representing 80% of revenue and driving the seasonal Q3 bookings spike.

AI & SASVA Platform

Sandeep Kalra: "we are using SASVA two ways. We are using SASVA to enable deal wins at scale and implementation at scale, and a number of times when we pitch SASVA the customer may not necessarily buy SASVA but customers understand our capabilities"

Margins

Margin walk (QoQ)Impact
Utilization improvement+20 bps
SG&A reduction+30 bps
Higher earn-out credit+20 bps
Favorable currency+40 bps
IP revenue headwind (managed services deals with lab setup, third-party tools/licenses)–40 bps
Net change → 15.6%+70 bps
Sandeep Kalra: "growth will always be priority number one, margin improvement priority number two"

Client Metrics & Deal Wins


Capital Allocation & M&A

Sandeep Kalra: "if we want to go into the newer verticals whether it is manufacturing or others we may do as we go along acquisitions so that we enter it with a dominant force rather than incubate and be a weaker player in that"

Guidance & Commitments

CommitmentSpecificsTimeline
Revenue targetReach $2 bn in revenueBy end of FY27
Margin aspirationImprove EBIT margin by 200–300 bps from FY25 levelsBy the time $2 bn revenue is achieved (FY27)
Effective tax rateRemain in 23% to 23.5% rangeGoing forward
OCFSustain above 100% of PATOngoing
Growth leadershipBFSI and Tech to lead growth, followed by Healthcare & Life SciencesFY26
M&A for new verticalsEnter manufacturing or other verticals via acquisition, not organic incubationAs opportunities arise

Key Metrics

MetricQ4 FY25
Revenue (USD)$375.2 million, +4.2% QoQ and +20.7% YoY
Revenue (INR)₹3,242.11 crore, +5.9% QoQ and +25.2% YoY
Constant currency revenue growth+4.5% QoQ, 20th sequential quarter of revenue growth
EBIT margin15.6%, +70 bps QoQ and +110 bps YoY
EBIT (INR)₹505.29 crore, +10.9% QoQ and +34.9% YoY
Profit after tax margin12.2%
Profit after tax (INR)₹395.76 crore, +25.5% YoY
Earnings per share₹25.60, +23% YoY
Full-year FY25 revenue (USD)$1,409.1 million, +18.8% YoY
Full-year FY25 EBIT margin14.7%, vs 14.4% in FY24
Full-year FY25 PAT margin11.7%, vs 11.1% in FY24
Total contract value (TCV)$517.5 million, with $329 million from new bookings
Annual contract value (ACV)$350.2 million, with $198.1 million from new bookings
Full-year FY25 TCV$2.1 billion, corresponding ACV of $1.5 billion
Top 10 customer revenue contribution42.2%, vs 40% in Q4 FY24
Healthcare & life sciences vertical growth+33.6% YoY
Banking & financial services vertical growth+26.6% YoY
Software, high-tech & emerging vertical growth+9.7% YoY
North America revenue growth+21.3% YoY
Europe revenue growth+30.6% YoY
Total headcount24,594, +744 YoY
Trailing 12-month attrition12.9%, vs 11.5% in Q4 FY24
Billed DSO58 days, improved 6 days QoQ
OCF to PAT108.4%
Return on capital employed (ex-cash)39.7%, vs 35.7% in Q4 FY24
Dividend per share (final recommended)₹15, total FY25 dividend ₹35 per share; payout ratio 39%
Effective tax rate21.7%, vs 22.6% in Q3; full-year FY25 23.2%
Forward contracts outstanding$300 million at average rate ₹86.3 per dollar
Data & AI practice growth50%+ in each of the last two years